• LY364947: TGF-β Type I Receptor Kinase Inhibitor in EMT Work

  2026-05-28

  LY364947 offers robust, selective inhibition of TGF-β signaling, empowering researchers to dissect EMT, fibrosis, and retinal degeneration pathways with precision. Its solubility profile and validated performance across in vitro and in vivo models set it apart as an indispensable tool for preclinical research.

• Safe DNA Gel Stain: Sensitive, Low-Mutagenic DNA/RNA Visuali

  2026-05-28

  Safe DNA Gel Stain is a highly sensitive and less mutagenic DNA and RNA gel stain, offering safer nucleic acid visualization compared to ethidium bromide. It supports excitation by both blue-light and UV, enhancing laboratory safety and cloning efficiency. This article details its mechanism, benchmarks, and workflow parameters.

• One-step TUNEL Cy5 Apoptosis Detection Kit: Workflow & Insig

  2026-05-27

  The One-step TUNEL Cy5 Apoptosis Detection Kit streamlines high-sensitivity detection of apoptosis in tissue sections and cultured cells, leveraging Cy5 fluorescence for robust quantification. Discover protocol refinements, advanced troubleshooting, and practical guidance directly linked to emerging research on programmed cell death.

• Cholecystokinin Octapeptide Ammonium: Workflow, Use-Cases &

  2026-05-27

  Cholecystokinin octapeptide ammonium (CCK-8 ammonium) unlocks advanced neurobehavioral and immunological research with unprecedented control over receptor-specific pathways. This guide distills validated protocols, troubleshooting strategies, and unique insights from the latest literature, ensuring your experiments achieve both mechanistic clarity and reproducible results.

• L-NMMA Acetate: Precision Tools for Nitric Oxide Pathway Mod

  2026-05-26

  Explore how L-NMMA acetate (N(G)-monomethyl-L-arginine acetate) unlocks targeted inhibition of nitric oxide synthase (NOS) pathways, enabling translational researchers to dissect cellular signaling in inflammation, regeneration, and disease. This article blends mechanistic insight, workflow guidance, and strategic foresight for leveraging L-NMMA acetate in advanced biomedical models, referencing landmark studies and protocol best practices.

• Applied Protocols with PKM2 Inhibitor (compound 3k) in Cance

  2026-05-26

  PKM2 inhibitor (compound 3k) empowers researchers to selectively disrupt tumor metabolism and dissect immune cell reprogramming. This guide details optimized workflows, troubleshooting strategies, and translational insights, bridging the latest reference breakthroughs with practical lab execution.

• 3-Aminobenzamide (PARP-IN-1): Precision PARP Inhibition in T

  2026-05-25

  3-Aminobenzamide (PARP-IN-1) delivers nanomolar efficacy and low toxicity for dissecting poly (ADP-ribose) polymerase biology across oxidative stress, diabetic nephropathy, and innate immunity models. This guide translates top-cited findings into practical workflows, protocol enhancements, and troubleshooting strategies, ensuring robust and reproducible results with APExBIO's trusted reagent.

• Reactive Oxygen Species Assay Kit: Advanced Live Cell ROS An

  2026-05-25

  Unlock precise, quantitative live-cell oxidative stress measurement with the APExBIO Reactive Oxygen Species Assay Kit. This guide offers actionable protocols, troubleshooting, and insights for redox biology, cancer, and respiratory disease research, setting your experiments ahead of the curve.

• Arrb2 Promotes M2 Macrophage Polarization to Attenuate Hepat

  2026-05-24

  This study reveals that Arrb2 expression in hepatocytes drives M2 macrophage polarization and thereby mitigates hepatic ischemia–reperfusion injury (IRI), mediated by upregulation of the metabolite 6-ketoLCA. These findings clarify a novel hepatocyte-macrophage communication axis, offering new mechanistic insight and potential experimental approaches for liver IRI research.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-05-23

  This study systematically investigates the pharmacokinetic variability and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight how disease-induced changes in transporter and enzyme expression, particularly involving P-glycoprotein and CYP450s, alter drug exposure and distribution, with implications for optimizing clinical dosing in MASLD/MASH therapy.

• Clathrin-Mediated Endocytosis in Grass Carp Reovirus Entry

  2026-05-22

  Wang et al. (2018) reveal that genotype III grass carp reovirus (GCRV104) enters host cells via clathrin-mediated, pH-dependent endocytosis. Their inhibitor-focused approach clarifies viral entry mechanisms, offering a methodological foundation for aquatic virology and antiviral screening.

• Advancing Hepatocyte Maturation: Strategic Insights on FH1

  2026-05-22

  This thought-leadership article explores how the FH1 small molecule (Catalog No. B3700) is reshaping the landscape of iPS cell-derived hepatocyte maturation, offering mechanistic depth, strategic guidance, and translational context for researchers developing next-generation liver models and therapies.

• Anisomycin: JNK Agonist Workflows for Apoptosis & Memory Res

  2026-05-21

  APExBIO's Anisomycin stands out for its reproducible JNK pathway activation, enabling advanced experimental designs in both cancer cell apoptosis and synaptic plasticity research. This article delivers stepwise protocol enhancements, troubleshooting strategies, and actionable insights from recent memory maintenance breakthroughs.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Applied Wor

  2026-05-21

  Unlock high-sensitivity mitochondrial membrane potential assays with the JC-1 kit, enabling robust apoptosis and mitochondrial function analysis. This guide delivers stepwise protocols, troubleshooting insights, and evidence-driven enhancements for reliable and quantitative ΔΨm detection—even in challenging experimental contexts.

• All-trans Retinoic Acid Reverses PARP Inhibitor Resistance i

  2026-05-20

  This study establishes that all-trans retinoic acid (ATRA) can resensitize epithelial ovarian cancer (EOC) cells to PARP inhibitors following cisplatin exposure by downregulating key resistance-associated genes and intracellular NAD+ levels. The findings offer a mechanistic basis for combining ATRA with PARP inhibitors in maintenance therapy, addressing a major clinical challenge in chemoresistant EOC.

481 records 12/33 page Previous Next First page 上5页 1112131415 下5页 Last page